Pharmacogenomics Market Size and Share
Pharmacogenomics Market Analysis by Mordor Intelligence
The Pharmacogenomics Market size is estimated at USD 10.27 billion in 2025, and is expected to reach USD 15.61 billion by 2030, at a CAGR of 8.73% during the forecast period (2025-2030).
Clinical adoption is expanding as health systems weave pre-emptive genetic testing into routine workflows, trimming trial-and-error prescribing and lowering adverse reactions. Medicare’s 2024 Local Coverage Determinations and the FDA’s companion-diagnostic guidance have created clearer reimbursement and regulatory pathways, encouraging laboratories to scale capacity. Demand accelerates in pain management, where CYP2D6 testing supports opioid stewardship and posts the fastest segment CAGR of 13.75%. Asia-Pacific shows double-digit growth as China and India embed pharmacogenomic programs in national health strategies. Meanwhile, AI-driven software platforms shorten interpretation time and increasingly steer buying decisions for hospitals.
Key Report Takeaways
- By product & service, reagents and kits led with 44.34% revenue share in 2024; software and services are projected to expand at an 11.01% CAGR to 2030.
- By technology, DNA sequencing held 32.66% of pharmacogenomics market share in 2024, while sequencing also records the highest forecast CAGR at 12.12%.
- By sample type, blood samples accounted for 58.47% share of the pharmacogenomics market size in 2024 and saliva testing is advancing at a 12.40% CAGR through 2030.
- By application, oncology captured 27.53% of pharmacogenomics market share in 2024; pain management is set to grow at a 13.75% CAGR to 2030.
- By geography, North America commanded 41.91% share of the pharmacogenomics market size in 2024, whereas Asia-Pacific is likely to accelerate at a 14.75% CAGR.
Global Pharmacogenomics Market Trends and Insights
Drivers Impact Analysis
Driver | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
---|---|---|---|
Rising Demand for Personalized Medicine | +2.1% | Global, with early adoption in North America & EU | Medium term (2-4 years) |
Advancements in Genetic Sequencing Technologies | +1.8% | Global, led by North America and Asia-Pacific | Short term (≤ 2 years) |
Growing Prevalence of Chronic and Genetic Diseases | +1.5% | Global, with highest impact in aging populations | Long term (≥ 4 years) |
Increasing Research and Development Investments | +1.2% | North America, EU, and emerging APAC markets | Medium term (2-4 years) |
High Incidence of Adverse Drug Reactions | +0.9% | Global, particularly in polypharmacy populations | Short term (≤ 2 years) |
Expanding Pharmaceutical and Biotechnology Industries | +0.8% | Global, with concentration in innovation hubs | Long term (≥ 4 years) |
Source: Mordor Intelligence
Rising Demand for Personalized Medicine
Health systems now view genetic testing as core infrastructure because outcome data show 42% fewer prescribing adjustments and higher adherence when pre-emptive panels are used.[1]Richard Weinshilboum, “Pharmacogenomics: Precision Medicine and the Mayo Clinic Experience,” Mayo Clinic Proceedings, mayoclinicproceedings.org The PREPARE multisite study reported a 33% drop in drug-related adverse events under pharmacogenomic guidance. Veterans Affairs has rolled out a nationwide program to align drug choice with veterans’ genotypes, moving away from one-size-fits-all prescribing. These benefits underpin steady pharmacogenomics market growth even in budget-constrained systems. Data-rich implementation models also help payers quantify long-term savings, strengthening coverage proposals.
Advancements in Genetic Sequencing Technologies
Illumina’s NovaSeq X has lowered per-sample costs while boosting throughput, making comprehensive panels affordable for community hospitals. Oxford Nanopore and PacBio long-read platforms now resolve CYP2D6 structural variants missed by earlier methods. A University of Illinois nanopore system compresses sequencing time from 2 weeks to 1 hour, cutting costs by 90% and enabling near-patient testing. Third-generation tools capture complex haplotypes in under-represented populations, closing equity gaps and expanding the addressable pharmacogenomics market. Faster, cheaper sequencing also frees budgets for informatics and counseling services.
Growing Prevalence of Chronic and Genetic Diseases
CYP2D6-guided opioid prescribing has been linked to a 6.14-fold cut in emergency visits among high-risk genotypes. Cardiovascular programs increasingly reference CYP2C19 results to optimize clopidogrel dosing and reduce stent thrombosis nature.com. Depression trials show shorter medication cycles and better symptom control when pharmacogenomic panels inform drug selection. Oncology remains a mainstay, with new FDA approvals such as RYTELO requiring biomarker-guided use.[2]Food and Drug Administration, “Table of Pharmacogenomic Biomarkers in Drug Labeling,” fda.gov Rising multimorbidity therefore sustains demand across multiple therapeutic silos within the pharmacogenomics market.
Increasing Research and Development Investments
Thermo Fisher has earmarked USD 40-50 billion for acquisitions that deepen its genomic toolkit, reinforcing scale advantages. Genomics plc extended its Vertex tie-up to mine big-data cohorts for variant-validated targets. QIAGEN launched five AI-enabled digital-insights modules to expedite panel design and clinical interpretation. Government genome programs in China and the Gulf add non-dilutive capital, catalyzing private follow-on rounds. This influx accelerates platform convergence, boosting the pharmacogenomics market beyond diagnostic kits into integrated drug-development workflows.
Restraints Impact Analysis
Restraint | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
---|---|---|---|
High Costs Associated with Pharmacogenomic Testing | -1.4% | Global, with highest impact in price-sensitive markets | Short term (≤ 2 years) |
Limited Reimbursement Coverage | -1.1% | Primarily North America and select EU markets | Medium term (2-4 years) |
Ethical and Privacy Concerns | -0.8% | Global, with varying regulatory frameworks | Long term (≥ 4 years) |
Lack of Clear Regulatory Guidelines | -0.6% | Emerging markets and regions with developing frameworks | Medium term (2-4 years) |
Source: Mordor Intelligence
High Costs Associated with Pharmacogenomic Testing
Comprehensive panels range from USD 200-2,000, creating affordability gaps for uninsured patients and small clinics. Rural providers also shoulder training and IT integration expenses, delaying roll-outs. Upfront investment in decision-support engines strains capital budgets, although modeling shows long-run savings from fewer adverse reactions. Bulk-purchasing consortia and machine-learning triage tools help curb per-test charges. Cost declines in reagents and sequencing hardware are expected to ease this restraint in the medium term.
Limited Reimbursement Coverage
UnitedHealthcare curtailed payment for multigene panels in 2024, affecting solutions such as GeneSight and prompting test bundling revisions. Medicare covers defined drug-gene pairs but stops short of blanket pharmacogenomic profiles, forcing providers to rely on piecemeal billing.[3]Centers for Medicare & Medicaid Services, “LCDs for Molecular Pathology Procedures,” cms.gov Although CPIC guidelines and updated drug labels support clinical utility, payer acceptance remains uneven. Demonstrating budget impact with robust real-world evidence is therefore essential for vendors seeking to broaden the pharmacogenomics market.
Segment Analysis
By Product & Service: Software-centric Transformation in Progress
Reagents and kits represented 44.34% of pharmacogenomics market share in 2024, underpinned by high test volumes and consumable pull-through. Yet software and services are expanding fastest at 11.01% CAGR, reflecting a pivot toward actionable insights over raw sequence data. Hospitals favor AI-assisted decision-support modules that plug directly into electronic health records, reducing interpretation time from hours to minutes. PGxAI’s Deneb model exemplifies this shift by blending pharmacogenetic calls with drug-response algorithms to inform dosing adjustments. Instruments remain a steady contributor as vendors integrate sample prep, amplification and analytics into single bencheside units, easing workflow complexity.
The convergence of wet-lab and digital components is redefining solution bundles within the pharmacogenomics market. QIAGEN’s QIAcuity digital PCR line added 100 assays in 2024 to support oncology, cardiology and pain panels. Service contracts now include tele-genetic counseling to meet accreditation standards for informed consent. As cloud infrastructure matures, subscription-based bioinformatics is displacing perpetual licenses, smoothing cash flow for both suppliers and clinics. These trends reinforce the pharmacogenomics market size trajectory by shifting revenue toward recurring analytics and support offerings.
Note: Segment shares of all individual segments available upon report purchase
By Technology: Sequencing Extends Leadership
DNA sequencing already commands 32.66% of pharmacogenomics market share and is projected to grow at 12.12% CAGR, lifted by falling reagent costs and richer variant detection. Illumina’s NovaSeq X platform reduced per-genome costs, unlocking population-scale screening for large health networks. Long-read instruments from PacBio map complex CYP2D6 rearrangements critical for opioid dosing.
Microarrays remain relevant for high-throughput targeted panels, especially the Infinium Global Diversity Array with 1.9 million PGx markers. PCR assays win where rapid turnaround is vital, such as perioperative antiplatelet management. Mass-spectrometry and electrophoresis retain niche roles. The net effect is continued consolidation around multi-omics sequencing hubs, strengthening the pharmacogenomics market.
By Sample Type: Saliva Collection Rises
Blood specimens held 58.47% of pharmacogenomics market size in 2024 due to entrenched lab protocols and robust DNA yield. Saliva kits, however, will post the highest 12.40% CAGR as non-invasive sampling increases patient compliance, especially in telehealth and pediatric settings. Validated chemistries now deliver comparable call rates to venous draws, erasing earlier quality concerns.
Remote enrollment programs mail saliva kits directly to participants, then upload results into cloud dashboards, a workflow well-suited to employer wellness plans. Buccal swabs and tissue biopsies fill disease-specific needs but remain minority contributors. Diversified specimen options improve reach among mobility-limited or rural cohorts, broadening the pharmacogenomics market.

Note: Segment shares of all individual segments available upon report purchase
By Application: Pain Management Surges Beyond Oncology
Oncology captured 27.53% of pharmacogenomics market share in 2024 through mandatory companion diagnostics. Pain management, though smaller, will expand at a 13.75% CAGR as CYP2D6 panels support safer opioid regimens. Veterans Affairs now screens veterans before opioid initiation, citing genetic evidence of differential metabolism.
Neurology benefits from pharmacoresistant epilepsy data guiding sodium-channel blocker choice, while cardiology programs integrate CYP2C19 status to fine-tune antiplatelet therapy. Drug-development teams also integrate PGx biomarkers to stratify clinical-trial subjects, aligning with FDA guidance for companion tests. Rising multi-therapy deployment cements the pharmacogenomics market as a cross-specialty platform rather than a single-disease niche.
Geography Analysis
North America accounted for 41.91% of the pharmacogenomics market in 2024, underpinned by mature lab infrastructure, CPIC implementation resources and supportive FDA frameworks. Mayo Clinic and University of Colorado provide blueprints for workflow integration, while the Veterans Affairs program extends reach across 9 million enrollees. Nonetheless, payer variability persists, with UnitedHealthcare’s 2024 coverage curbs dampening multigene panel uptake myriad.com.
Europe shows steady advances as the European Medicines Agency finalized AI-driven pharmacogenomic guidance in 2024, giving manufacturers clarity to scale companion-diagnostic submissions. National health services in France, Germany and the Nordics are piloting population panels to measure long-term cost offsets, promoting broader pharmacogenomics market penetration.
Asia-Pacific is the fastest-growing region, forecast at 14.75% CAGR. China’s Five-Year Health Plan embeds pharmacogenomic screening into public hospitals and secures domestic sequencing supply chains. Indian start-ups like Acrannolife provide locally priced PGx bundles for cardiology and psychiatry. Singapore research found 46.1% of participants carried actionable CYP2D6 alleles, underscoring unmet need nature.com. Expansive population cohorts and diverse haplotypes augment global biomarker discovery pipelines, amplifying the overall pharmacogenomics market size.

Competitive Landscape
The sector is moderately concentrated, with Illumina, Thermo Fisher Scientific and Roche anchoring sequencing and assay ecosystems. Illumina bundles hardware with cloud informatics and boasts extensive regulatory dossiers, securing preferred-vendor status in many integrated delivery networks. Thermo Fisher’s multi-billion-dollar acquisition budget seeks analytic software and companion-diagnostic assets that complement its Ion Torrent and KingFisher lines. Roche extends Foundation Medicine partnerships to integrate PGx endpoints into oncology trials.
Software-first entrants raise competitive intensity. PGxAI uses transformer-based models to predict drug-gene interactions and recently signed pilots with 50 US hospitals. PillHarmonics embeds alerts in e-prescribing systems, lowering deployment friction. QIAGEN leverages its digital insights unit to cross-sell bioinformatics subscriptions alongside sample-prep consumables.
Regional players round out the field. China’s Berry Genomics markets CFDA-cleared PGx panels, while Australia’s GeneByGene partners with pharmacies for direct-to-consumer kits. As technology stacks converge, differentiation shifts toward integrated services, data security and payer engagement strategies that expand the pharmacogenomics market.
Pharmacogenomics Industry Leaders
-
Thermo Fisher Scientific Inc.
-
F. Hoffmann-La Roche AG
-
Bio-Rad Laboratories
-
Abbott Laboratories
-
bioMérieux
- *Disclaimer: Major Players sorted in no particular order

Recent Industry Developments
- June 2025: University of Illinois researchers developed a novel nanopore sensing platform that reduces DNA sequencing time from 2 weeks to 1 hour while cutting costs by 90%, potentially revolutionizing point-of-care pharmacogenomic testing capabilities. This breakthrough addresses critical barriers to clinical implementation by enabling rapid genetic analysis in routine healthcare settings.
- April 2025: PGxAI launched the Deneb AI model designed to revolutionize drug development by integrating pharmacogenetics with artificial intelligence, representing a significant advancement in precision medicine technology platforms. The platform aims to optimize therapeutic decisions through enhanced genetic data interpretation and clinical decision support.
- May 2024: Oxford Nanopore Technologies introduced a new Pharmacogenomics (PGx) Beta Programme for advancing personalized medicine with the combination of Twist Bioscience’s next-generation sequencing (NGS) target enrichment technology with Oxford Nanopore’s sequencing platform.
- February 2024: Nicklaus Children's Hospital in South Florida adopted the next-generation pharmacogenomics technology, Applied Biosystems PharmacoScan Solution and GeneTitan MC Fast Scan Instrument, to develop personalized treatment plans for the patients and reduce the complications from drug interactions and side effects.
Global Pharmacogenomics Market Report Scope
As per the scope of this report, pharmacogenomics provides accurate insights into making clinical decisions and determining the most effective treatment by varying the dosages of drugs. The field of pharmacogenomics is predicted to treat a wide range of health problems, including cardiovascular diseases, Alzheimer's disease, cancer, HIV/AIDS, and asthma. The pharmacogenomics market is segmented by technology, application, and geography. By technology, the market is segmented into DNA sequencing, microarray, polymerase chain reaction, electrophoresis, mass spectrometry, and other technologies. By application, the market is segmented into drug discovery, neurology, oncology, pain management, and other applications. By geography, the market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and South America. For each segment, the market size is provided in terms of value (USD).
By Product & Service | Instruments | ||
Reagents & Kits | |||
Software & Services | |||
By Technology | Polymerase Chain Reaction (PCR) | ||
DNA Sequencing | |||
Microarray | |||
Mass Spectrometry | |||
Electrophoresis | |||
Other Technologies | |||
By Sample Type | Blood | ||
Saliva | |||
Other Biospecimens | |||
By Application | Drug Discovery & Development | ||
Oncology | |||
Neurology | |||
Cardiology | |||
Pain Management | |||
Other Therapeutic Areas | |||
By Geography | North America | United States | |
Canada | |||
Mexico | |||
Europe | Germany | ||
United Kingdom | |||
France | |||
Italy | |||
Spain | |||
Rest of Europe | |||
Asia-Pacific | China | ||
Japan | |||
India | |||
Australia | |||
South Korea | |||
Rest of Asia-Pacific | |||
Middle East & Africa | GCC | ||
South Africa | |||
Rest of Middle East & Africa | |||
South America | Brazil | ||
Argentina | |||
Rest of South America |
Instruments |
Reagents & Kits |
Software & Services |
Polymerase Chain Reaction (PCR) |
DNA Sequencing |
Microarray |
Mass Spectrometry |
Electrophoresis |
Other Technologies |
Blood |
Saliva |
Other Biospecimens |
Drug Discovery & Development |
Oncology |
Neurology |
Cardiology |
Pain Management |
Other Therapeutic Areas |
North America | United States |
Canada | |
Mexico | |
Europe | Germany |
United Kingdom | |
France | |
Italy | |
Spain | |
Rest of Europe | |
Asia-Pacific | China |
Japan | |
India | |
Australia | |
South Korea | |
Rest of Asia-Pacific | |
Middle East & Africa | GCC |
South Africa | |
Rest of Middle East & Africa | |
South America | Brazil |
Argentina | |
Rest of South America |
Key Questions Answered in the Report
What is the current value of the pharmacogenomics market?
The pharmacogenomics market is valued at USD 10.27 billion in 2025 and is projected to reach USD 15.61 billion by 2030.
Which segment is growing the fastest within the pharmacogenomics market?
Pain management is the fastest-growing application, forecast to expand at a 13.75% CAGR as CYP2D6 testing gains traction.
Why is DNA sequencing important for pharmacogenomics?
DNA sequencing delivers the broad variant coverage needed for multi-gene drug-response panels, holding 32.66% market share and a 12.12% CAGR.
Which region will see the highest pharmacogenomics market growth?
Asia-Pacific is expected to post the highest regional CAGR at 14.75% thanks to large-scale government precision-medicine programs.
What challenges limit wider pharmacogenomics adoption?
High per-test costs and inconsistent reimbursement policies remain primary barriers, though evidence of clinical utility is gradually easing payer resistance.
Who are the leading companies in pharmacogenomics?
Illumina, Thermo Fisher Scientific and Roche dominate sequencing and assay platforms, while software innovators such as PGxAI are emerging rapidly.
Page last updated on: June 18, 2025